Related references
Note: Only part of the references are listed.Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects
Jason Charles Ray et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial
Paul K. Winner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine
Brian Baker et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Headaches in the emergency department -a survey of patients' characteristics, facts and needs
Alberto Doretti et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Migraine is first cause of disability in under 50s: will health politicians now take notice?
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Safety and Efficacy of IV Lidocaine in the Treatment of Children and Adolescents With Status Migraine*
Marco Antonio Ayulo et al.
PEDIATRIC CRITICAL CARE MEDICINE (2018)
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series
Clinton Lauritsen et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings
Serena L. Orr et al.
CEPHALALGIA (2015)
Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review
R. Gil-Gouveia et al.
CEPHALALGIA (2009)
Intravenous lignocaine infusions for severe chronic daily headache
PJ Hand et al.
MEDICAL JOURNAL OF AUSTRALIA (2000)
Share Paper
